Hamlet BioPharma has signed an agreement with the Korean biotech company ImmunoForge, to develop novel administration technology for the peptide drug NZX, for use in patients with tuberculosis.
Tuberculosis is a major cause of mortality in all parts of the world and treatment options are becoming more limited, due to escalating antibiotic resistance. The antimicrobial peptide NZX is being developed as a drug candidate for pulmonary tuberculosis treatment, in collaboration with Hamlet BioPharma. The new, peptide-based drug has shown promising treatment effects against lung tuberculosis in animal models, both against antibiotic sensitive and antibiotic-resistant Mycobacterium tuberculosis bacteria.
ImmunoForge based in Seoul, South Korea, who are developing novel drug delivery techniques for clinical use, contacted Hamlet BioPharma to initiate this collaboration. The company will develop novel administration technology for the NZX peptide, specifically a slow-release technology that would prolong the effect of each treatment.
The future rights to the results of the collaboration will be jointly owned by the two companies, as well as future patent rights.
https://www.immunoforge.com/en/
For more information please contact:
Catharina Svanborg, Chairman of the Board, Hamlet BioPharma, +46-709 42 65 49
catharina.svanborg@hamletpharma.com
Jakob Testad, CEO, Hamlet BioPharma, +46-708 48 42 10